Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.

Forman M, Palcza J, Tseng J, Stone JA, Walker B, Swearingen D, Troyer MD, Dockendorf MF.

Clin Transl Sci. 2019 Sep;12(5):545-555. doi: 10.1111/cts.12645. Epub 2019 Jun 19.

2.

Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.

Chris Min K, Dockendorf MF, Palcza J, Tseng J, Ma L, Stone JA, Kleijn HJ, Hodsman P, Masuo K, Tanen M, Troyer MD, van Vugt M, Forman MS.

Clin Pharmacol Ther. 2019 May;105(5):1234-1243. doi: 10.1002/cpt.1258. Epub 2019 Jan 18.

PMID:
30347431
3.

Asenapine pharmacokinetics and tolerability in a pediatric population.

Dogterom P, Riesenberg R, de Greef R, Dennie J, Johnson M, Pilla Reddy V, Miltenburg AM, Findling RL, Jakate A, Carrothers TJ, Troyer MD.

Drug Des Devel Ther. 2018 Aug 30;12:2677-2693. doi: 10.2147/DDDT.S171475. eCollection 2018.

4.

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.

Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF, Egan M, Ereshefsky L, Hodgson RA, Hyde LA, Jhee S, Kleijn HJ, Kuvelkar R, Li W, Mattson BA, Mei H, Palcza J, Scott JD, Tanen M, Troyer MD, Tseng JL, Stone JA, Parker EM, Forman MS.

Sci Transl Med. 2016 Nov 2;8(363):363ra150.

PMID:
27807285
5.

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.

Vermeeren A, Vets E, Vuurman EF, Van Oers AC, Jongen S, Laethem T, Heirman I, Bautmans A, Palcza J, Li X, Troyer MD, Wrishko R, McCrea J, Sun H.

Psychopharmacology (Berl). 2016 Sep;233(18):3341-51. doi: 10.1007/s00213-016-4375-x. Epub 2016 Jul 16.

6.

Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.

Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA.

J Clin Psychopharmacol. 2016 Aug;36(4):314-23. doi: 10.1097/JCP.0000000000000516.

PMID:
27253658
7.

Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.

Sun H, Yee KL, Gill S, Liu W, Li X, Panebianco D, Mangin E, Morrison D, McCrea J, Wagner JA, Troyer MD.

J Psychopharmacol. 2015 Nov;29(11):1159-69. doi: 10.1177/0269881115609015. Epub 2015 Oct 13. Erratum in: J Psychopharmacol. 2016 Jan;30(1):95.

PMID:
26464455
8.

Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.

Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD.

J Clin Sleep Med. 2016 Jan;12(1):9-17. doi: 10.5664/jcsm.5382.

9.

On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.

Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers AC, Palcza J, Li X, Laethem T, Heirman I, Bautmans A, Troyer MD, Wrishko R, McCrea J.

Sleep. 2015 Nov 1;38(11):1803-13. doi: 10.5665/sleep.5168.

10.

Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.

Uemura N, McCrea J, Sun H, Donikyan M, Zammit G, Liu R, Louridas B, Marsilio S, Lines C, Troyer MD, Wagner J.

J Clin Pharmacol. 2015 Oct;55(10):1093-100. doi: 10.1002/jcph.523. Epub 2015 Jun 3.

PMID:
25903940
11.

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA; Parkinson's Progression Markers Initiative.

Mov Disord. 2015 Jun;30(7):919-27. doi: 10.1002/mds.26170. Epub 2015 Mar 4.

12.

Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.

Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, Lines C, Wagner JA, Troyer MD.

Respir Med. 2015 Mar;109(3):416-26. doi: 10.1016/j.rmed.2014.12.010. Epub 2015 Jan 5.

13.

A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design.

Peng JZ, Denney WS, Musser BJ, Liu R, Tsai K, Fang L, Reitman ML, Troyer MD, Engel SS, Xu L, Stoch A, Stone JA, Kowalski KG.

AAPS J. 2014 Nov;16(6):1259-70. doi: 10.1208/s12248-014-9648-x. Epub 2014 Aug 27.

14.

Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.

De Kam PJ, Kruithof AC, van Lierop MJ, Moerland M, Dennie J, Troyer MD, Langdon RB, Gutstein DE, Burggraaf J, El Galta R.

Int J Clin Pharmacol Ther. 2014 Aug;52(8):631-41. doi: 10.5414/CP202091.

PMID:
24800921
15.

No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters.

de Kam PJ, El Galta R, Kruithof AC, Fennema H, van Lierop MJ, Mihara K, Burggraaf J, Moerland M, Peeters P, Troyer MD.

Int J Clin Pharmacol Ther. 2013 Dec;51(12):976-85. doi: 10.5414/CP201970.

PMID:
24120718
16.

Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.

Wang Z, Xuan F, Lin WH, Troyer MD, Tendolkar A, Cutler DL.

Eur J Clin Pharmacol. 2013 Oct;69(10):1761-7. doi: 10.1007/s00228-013-1541-5. Epub 2013 Jul 16.

PMID:
23857248
17.

Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia.

Egan MF, Zhao X, Smith A, Troyer MD, Uebele VN, Pidkorytov V, Cox K, Murphy M, Snavely D, Lines C, Michelson D.

Hum Psychopharmacol. 2013 Mar;28(2):124-33. doi: 10.1002/hup.2289.

PMID:
23532746
18.

Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents.

Yang ZQ, Schlegel KA, Shu Y, Reger TS, Cube R, Mattern C, Coleman PJ, Small J, Hartman GD, Ballard J, Tang C, Kuo Y, Prueksaritanont T, Nuss CE, Doran S, Fox SV, Garson SL, Li Y, Kraus RL, Uebele VN, Taylor AB, Zeng W, Fang W, Chavez-Eng C, Troyer MD, Luk JA, Laethem T, Cook WO, Renger JJ, Barrow JC.

ACS Med Chem Lett. 2010 Aug 24;1(9):504-9. doi: 10.1021/ml100170e. eCollection 2010 Dec 9.

19.

Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.

Iwamoto M, Kassahun K, Troyer MD, Hanley WD, Lu P, Rhoton A, Petry AS, Ghosh K, Mangin E, DeNoia EP, Wenning LA, Stone JA, Gottesdiener KM, Wagner JA.

J Clin Pharmacol. 2008 Feb;48(2):209-14. Epub 2007 Dec 12.

PMID:
18077730
20.

Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis.

Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, Savalle M, Nemani V, Chaudhry FA, Edwards RH, Stefanis L, Sulzer D.

J Neurosci. 2006 Nov 15;26(46):11915-22.

21.

Alpha-synuclein overexpression increases cytosolic catecholamine concentration.

Mosharov EV, Staal RG, Bové J, Prou D, Hananiya A, Markov D, Poulsen N, Larsen KE, Moore CM, Troyer MD, Edwards RH, Przedborski S, Sulzer D.

J Neurosci. 2006 Sep 6;26(36):9304-11.

22.

Lipid rafts mediate the synaptic localization of alpha-synuclein.

Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH.

J Neurosci. 2004 Jul 28;24(30):6715-23.

23.

The expression of vesicular glutamate transporters defines two classes of excitatory synapse.

Fremeau RT Jr, Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ, Bellocchio EE, Fortin D, Storm-Mathisen J, Edwards RH.

Neuron. 2001 Aug 2;31(2):247-60.

24.

Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders.

Loeffler DA, LeWitt PA, Juneau PL, Sima AA, Nguyen HU, DeMaggio AJ, Brickman CM, Brewer GJ, Dick RD, Troyer MD, Kanaley L.

Brain Res. 1996 Nov 4;738(2):265-74.

PMID:
8955522
25.

Supplemental Content

Loading ...
Support Center